Prevention of delayed cerebral vasospasm by continuous intrathecal infusion of glyceroltrinitrate and nimodipine in the rabbit model in vivo by Marbacher, Serge et al.
Intensive Care Med (2008) 34:932–938
DOI 10.1007/s00134-008-0995-x E X PER I MEN T A L
Serge Marbacher
Volker Neuschmelting
Thilo Graupner
Stephan M. Jakob
Javier Fandino
Prevention of delayed cerebral vasospasm by
continuous intrathecal infusion of glycerol-
trinitrate and nimodipine in the rabbit model in
vivo
Received: 8 July 2007
Accepted: 21 December 2007
Published online: 24 January 2008
© Springer-Verlag 2008
Electronic supplementary material
The online version of this article
(doi:10.1007/s00134-008-0995-x) contains
supplementary material, which is available
to authorized users.
This study was supported by the
Cerebrovascular Research Fund from the
Departments of Neurosurgery and Intensive
Care Medicine (account no. 34-160),
University of Berne, Switzerland.
S. Marbacher · V. Neuschmelting ·
T. Graupner · S. M. Jakob · J. Fandino ()
University Hospital, Department
of Intensive Care Medicine,
Freiburgstrasse 10, 3010 Berne, Switzerland
e-mail: javier.fandino@ksa.ch
Tel.: +41-62-8386693
S. Marbacher · V. Neuschmelting ·
T. Graupner · J. Fandino
University Hospital, Department
of Neurosurgery,
Freiburgstrasse 10, 3010 Berne, Switzerland
J. Fandino
Kantonsspital Aarau, Department
of Neurosurgery,
Aarau, Switzerland
Abstract Objective: Intrathecal
bolus administration of nitric oxide
donors and calcium channel antag-
onists has been proposed to reduce
cerebral vasospasm (CVS) in animal
subarachnoid hemorrhage (SAH)
models. Intrathecal continuous ad-
ministration of these substances
for CVS prevention has not been
extensively evaluated. This study
compared the efficacy of continuous
intrathecal infusions of the NO donor
glyceroltrinitrate and nimodipine in
preventing delayed CVS associated
with SAH in an animal model in
vivo. Methods: New Zealand White
rabbits were randomly assigned to six
groups: no SAH/NaCl, no SAH/NO,
no SAH/nimodipine, SAH/NaCl,
SAH/NO, or SAH/nimodipine. Glyc-
eroltrinitrate (GTN) at 0.5 µg/µl
(0.5 µl/h) or nimodipine at 0.2 µg/µl
(10 µl/h) or NaCl was continuously
infused into the cisterna magna
via an Alzet osmotic pump from
day 0 to day 5 after injection of
1.0 ml autologous blood. The mag-
nitude of spasm in the basilar artery
was determined by comparison of
pre- and posttreatment angiography
and was calculated as proportional
change in intraluminal diameter
based on automatic measurements.
Results: A total of 55 experiments
and 110 angiograms were performed.
SAH was associated with vaso-
constriction of the basilar artery
(SAH/NaCl group 19.85 ± 2.94%).
Continuous intrathecal injection of
GTN and nimodipine prevented
SAH-induced CVS. There was
significant prevention of CVS in
animals treated with GTN (SAH/NO
group 5.93 ± 5.2%, n = 11) and ni-
modipine (SAH/nimodipine group:
0.55 ± 2.66%, n = 9). There was no
significant difference between the
treatment groups and controls in pre-
vention of CVS. Conclusions: This
study demonstrates that prophylactic
continuous intrathecal administration
of either GTN or nimodipine equally
prevents SAH-associated CVS in an
animal model.
Keywords Subarachnoid hemor-
rhage · Vasospasm · Animal models ·
Nitric oxide · Nimodipine
Introduction
Symptomatic delayed cerebral vasospasm (DCV) develops
in approx. 30% of patients after aneurysmal subarachnoid
hemorrhage (SAH) and remains one of the major causes
of serious morbidity and death [1, 2]. Brain ischemic
events secondary to cerebral vasospasm (CVS) classically
occur 4–12 days after initial bleeding [3]. The exact cause
of CVS is unknown despite awareness of the entity for
almost half a century. Although the treatment protocol of
hypervolemia, hemodilution, and hypertension (“triple-H
therapy”) in combination with intravenous nimodipine ad-
ministration has had a substantial beneficial effect in CVS
treatment [4], in some patients the protocol is not tolerated
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or is ineffective [5–7]. Despite our increased knowledge
of the molecular basis of DCV following SAH no current
treatment modalities offer prophylactic prevention. Pre-
liminary case series in humans [8–11] and experimental
studies in a variety of animal models [12–17] suggest
that intrathecal administration of an NO donor would
be an effective treatment for reversing CVS. Controlled-
release polymers such as diethyl-amine-triamine/NO
and ethylene-vinyl acetate copolymer implanted in the
subarachnoid space close to the experimental bleeding site
serve as NO donors in most recent animal models with
intrathecal administration of the drugs [12–18]. Further-
more, sodium nitroprusside (SNP) and glyceroltrinitrate
(GTN) have served as NO donor to prevent CVS after
SAH [8–11, 19, 20].
Nimodipine, the most widely administered calcium
channel blocker, is a dihydropyridine calcium channel
antagonist that has been shown to decrease the incidence
of overall cerebral infarction after SAH by 34% and
the incidence of poor outcomes by 40% [21]. Whereas
intravenous or oral administration of nimodipine does not
appear to decrease the incidence of angiographic CVS [22,
23], intraoperative bathing of vessels in nimodipine solu-
tion and intrathecal bolus administration has demonstrated
reversal of spasm and dilatation of nonspastic vessels,
without changes in mean arterial blood pressure [24–29].
The present study compared the efficacy of continuous
intrathecal infusions of the NO donor glyceroltrinitrate
and nimodipine in preventing CVS in the rabbit SAH
model in vivo.
Materials and methods
The protocol of this study was reviewed and approved by
the Swiss Institutional Animal Care and Use Committee
Body PaCO2 PaO2 MABP HR
weight (kg) (mmHg) (mmHg) (mmHg) (per min)
no SAH/NaCl
Day 0 3.6 ± 0.1 51.70 ± 0.95 50.52 ± 8.6 65.5 ± 4.04 162 ± 5
Day 5 3.6 ± 0.1 43.60 ± 3.30 57.20 ± 1.3 56.20 ± 6.64 174 ± 7
no SAH/NO
Day 0 3.7 ± 0.2 44.00 ± 1.97 54.72 ± 3.7 64.33 ± 2.89 157 ± 4
Day 5 3.7 ± 0.2 45.75 ± 7.34 57.31 ± 4.1 55.33 ± 4.96 155 ± 8
no SAH/nimodipine
Day 0 2.7 ± 0.1 49.43 ± 1.82 63.24 ± 4.2 77.83 ± 3.43 178 ± 10
Day 5 2.7 ± 0.1 50.23 ± 1.77 61.04 ± 4.9 70.50 ± 2.62 181 ± 6
SAH/NaCl
Day 0 3.8 ± 0.2 45.37 ± 1.63 67.27 ± 5.2 72.50 ± 3.95 163 ± 4
Day 5 3.8 ± 0.2 41.36 ± 3.68 63.07 ± 4.1 59.83 ± 2.68 171 ± 7
SAH/NO
Day 0 3.8 ± 0.1 43.52 ± 2.16 64.80 ± 3.2 67.33 ± 3.40 179 ± 5
Day 5 3.8 ± 0.1 44.03 ± 2.57 62.98 ± 8.5 65.00 ± 4.95 163 ± 7
SAH/nimodipine
Day 0 3.1 ± 0.2 48.68 ± 1.43 67.05 ± 3.4 75.83 ± 2.52 191 ± 9
Day 5 3.1 ± 0.2 48.30 ± 1.68 74.07 ± 6.5 71.17 ± 2.09 178 ± 7
Table 1 Measurements of
physiological parameters
(PaCO2, arterial carbon dioxide
pressure; PaO2, arterial oxide
pressure; MABP, mean arterial
blood pressure; HR, heart rate)
and meets the Swiss guidelines for laboratory animal use
(Department of Veterinary Service, Berne, Switzerland,
approval no. 125/05).
Study design
A total of 55 adult New Zealand White rabbits of either sex
weighing 2.6–3.6 kg were randomly assigned to six exper-
imental groups. The groups did not differ significantly in
body weight, PaCO2, mean arterial blood pressure, or heart
rate at baseline (day 0) or at follow-up (day 5; Table 1).
Anesthesia, monitoring, and killing
Induction of general anesthesia was performed by
intramuscular administration of ketamine (30 mg/kg;
Ketalar, 50 mg/ml, Pfizer, Zurich, Switzerland) and xy-
lazine (6 mg/kg; Xylapan 20 mg/ml, Vetoquinol, Bern,
Switzerland). During surgery pain was evaluated pe-
riodically by toe-pinch. Postoperative pain relief was
managed by subcutaneous administration of buprenor-
phine (0.1–0.2 mg/kg) for up to 36 h after SAH. Heart rate
and blood pressure were monitored throughout the digital
subtraction angiography (DSA) on day 0 and day 5 after
experimental SAH. Intravascular pressures and heart rate
were measured with a Camino multiparameter monitor
(Integra, Plainsboro, NJ, USA). On the same days arterial
blood gas status was analyzed to monitor oxygenation
parameters from a collected arterial blood sample (ABL
725, Radiometer, Copenhagen, Denmark). The animals
underwent daily clinical observation. The animals were
killed on day 5 post-SAH induction under the same anes-
thetic as the angiography by intra-arterial bolus injection
of sodium thiopenthal (40 mg/kg) (Pentothal, Ospedalia,
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Hünenberg, Switzerland). Postmortem examination of
operative scars, pump, and tube position was performed
to evaluate signs of infection and to affirm correct sil-
icone catheter connection to the pump and unchanged
catheter location within the subarachnoid space of the
atlanto-occipital cistern.
Angiography
DSA was performed under general anesthesia on day 0
prior to SAH and on day 5 post-SAH. The rabbit’s left
(day 0) or right (day 5) subclavian artery was microsur-
gically exposed and cannulated using a 0.5 mm plastic
tube. The catheter was introduced retrogradely and fixed
distally to the origin of the vertebral artery. Subsequently
the DSA was performed by intra-arterial bolus injection of
nonionic iopamidol (0.6 ml/kg; Abott Laboratories, North
Chicago, IL, USA) as contrast agent. Images of the verte-
brobasilar system were obtained using a rapid sequential
angiographic technique with the small focal spot at 66 kV,
125 mA (DFP 2000A, Toshiba, Japan). Measurement
of each vessel was performed three times in a blinded
fashion by using the automatic measurement tool of the
ImagePro Discovery analysis software (MediaCybernet-
ics, Silver Spring, MD, USA), and mean values were
determined.
Induction of experimental SAH
Following baseline DSA on day 0, the atlanto-occipital
membrane was exposed, and a 25-gauge needle was
inserted into the cerebromedullar cistern. After relief of
1.0 ml CSF an equal amount of unheparinized autologous
arterial blood was injected into the cistern under micro-
scopic view. The rabbits were kept positioned at a 65°
angle head-down for 10 min to allow blood dissemination
throughout the subarachnoidal space (Fig. 1).
Miniosmotic pump implantation
Depending on the study group, a miniosmotic pump
(0.5 µl/h, Alzet Osmotic Pumps, Durect, Cupertino, CA,
USA) containing 0.5 mg/ml GTN solution (Perlinganit,
Schwarz Pharma, Münchenstein, Switzerland) or a min-
iosmotic pump (10 µl/h, Alzet) containing 0.2 mg/ml
nimodipine solution (Nimotop, Bayer HealthCare, Co-
logne, Germany) was implanted subcutaneously. Dose-
response curves of intrathecal GTN and nimodipine are
not available. The dose of GTN was derived from studies
in humans in which up to 8 mg/24 h was used for prophy-
laxis against vasospasm [8, 9]. The pH value of the GTN
and nimodipine solution was 7.35 and 7.4, respectively.
The dose of nimodipine was calculated from studies in
Fig. 1 Axial computer tomography demonstrates the successful dis-
semination of blood after cisterna magna injection. Arrow, Hyper-
dense prepontine blood collection
canine models [26, 27]. The rabbit’s CSF volume was
estimated to be 70–80 times less than that in humans
and 5–10 times less than that in dogs [30, 31]. Pumps,
associated tubing, and drugs were protected from light
at all times. A silicone catheter (STH-C040, Connectors
Verbindungstechnik, Tagelswangen, Switzerland) was
connected with the pump and inserted at least 1 mm
through the atlanto-occipital membrane into the subarach-
noid space. The tube insertion site was sealed by a muscle
patch and fixed by several stitches. The midline spinal
muscle incision was closed in two layers. Finally, the
wounds were superficially irrigated with neomycin sulfate
(Research Organics, Cleveland, OH, USA) for infection
prophylaxis. All surgical procedures were performed
under sterile conditions.
Statistical methods
Values were expressed as means of each group ± SEM
(n = number of animals). Statistical significance between
two means was determined by Student’s unpaired t test
and significance between multiple means was determined
by analysis of variance.
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Results
Mortality, morbidity, and neurological status
Two animals died immediately after injection of auto-
logous blood into the atlanto-occipital cistern as a result
of respiratory arrest. All other animals were in bland
neurological condition after the angiographic and surgi-
cal procedures and did not develop delayed neurological
deficits, with the exception of one animal in the SAH/NaCl
control group, which exhibited transient paresis of the
hind legs on day 2 after experimental SAH. Clinical daily
follow-up of the animals was uneventful up to day 5 when
they were killed. Gross pathological evaluation revealed
no signs of infection. All of the implanted pump devices
were placed in accurate position 1–2 mm underneath the
atlanto-occipital membrane.
Angiographic measurements
A total of 110 angiographic vessel diameters of the
rabbit basilar artery were investigated in the six groups.
Angiographic measurements and diameter changes in per-
centages are given in Table 2 and Fig. 2, respectively. The
baseline vessels’ diameter on day 0 did not differ signifi-
cantly among the six experimental groups. The data show
that SAH and plain saline infusion were associated with
vasoconstriction of the basilar artery (SAH/NaCl group
19.85 ± 2.94%; no SAH/NaCl group 14.92 ± 4.49%;
Table 2). The continuous intrathecal infusion of both ni-
modipine and GTN significantly reduced SAH-associated
vasoconstriction (SAH/nimodipine 0.55 ± 2.66%, n = 9,
vs. SAH/NaCl 19.85 ± 2.94%, n = 8, p < 0.005; SAH/NO
5.93 ± 5.2%, n = 11, vs. SAH/NaCl:19.85 ± 2.94%, n = 8,
p < 0.05). The comparison of the effects of nimodipine
and GTN on diameter changes after SAH showed no
statistical difference.
Discussion
The results of this study demonstrate nearly complete
prevention of delayed CVS of the rabbit basilar artery in
response to continuous intrathecal infusion of GTN or
n Diameter (µm) Diameter
Day 0 Day 5 reduction (%)
no SAH/NaCl 11 669.51 ± 2.97 593.59 ± 3.03 14.92 ± 4.49
no SAH/NO 9 676.03 ± 1.27 625.18 ± 1.14 5.67 ± 2.92
no SAH/nimodipine 7 730.04 ± 2.60 733.88 ± 5.90 0.32 ± 2.30
SAH/NaCl 8 688.71 ± 1.81 542.60 ± 1.70 19.85 ± 2.94
SAH/NO 11 648.21 ± 1.38 637.26 ± 2.26 5.93 ± 5.20**
SAH/nimodipine 9 726.58 ± 3.85 713.68 ± 3.18 0.55 ± 2.66*
*p < 0.001, **p < 0.05 vs. control group SAH/NaCl
Table 2 Summary of the effect
of continuous intrathecal nitro-
glycerin and nimodipine infusion
on basilar artery caliber (µm) in
rabbits with experimental SAH.
Values are expressed as the
mean ± standard error of mean
Fig. 2 Bar graph shows the results of the effect of continuous in-
tracisternal administration of nitric oxide donor (nitroglycerin) and
nimodipine on cerebral vasospasm after experimental subarrachnoid
hemorrhage in rabbits in vivo. The SAH/NO donor group (n = 11)
and the SAH/nimodipine group (n = 9) both demonstrate significant
prevention (**p = 0.0031, ***p = 0.0002) of the basilar artery
spasm compared to the control SAH/Saline group (n = 8) 5 days
postexperimental subarrachnoid hemorrhage. There was no signif-
icant (p = 0.3741) difference in the efficacy of spasm reduction
between the SAH/NO donor group and the SAH/nimodipine group.
There was also no significant difference between the no SAH/NO
group (n = 9) and the SAH/NO group (p = 0.9622) or between the
no SAH/nimodipine (n = 7) group and the SAH/nimodipine group
(p = 0.9507). Nimo, Nimodipine
nimodipine and therefore confirms previous promising re-
sults with intrathecal use of these two compounds [12–17,
24–29, 32]. In the presented experimental setting they
showed no significant difference in their efficacy.
NO is the smallest biologically active molecule known.
As a highly diffusible gas it mediates an extraordinary
range of physiological processes [33, 34]. The role of
NO in the context of SAH began when the identity of
the hypothetical endothelium-derived relaxing factor and
NO was recognized [35–37]. Ongoing research revealed
further extensive roles of NO in neurotransmission, in-
flammation, and vascular autoregulation [38]. In particular
NO appears to decrease vascular inflammation (one of
the key pathways in delayed CVS) [39, 40], serves as
a high potent vasodilating agent [41], and regulates the
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cerebral vascular tone as antagonist of the most potent
vasoconstrictor ET-1 [42]. Due to the short half-life,
side effects, and potential toxicity of NO in clinical
use, investigators in the past have focused on treating
experimental CVS by using intrathecal and periadventitial
soluble administration or polymer placements of NO
and NOD (see Table 1, see ESM) [12–17]. Most of the
performed animal studies used diethylenetriamine nitric
oxide donor from a controlled release polymer to pre-
vent CVS after experimental SAH [13, 15–17]. Thomas
et al. [8] and Kumar et al. [11] published preliminary
results of effective treatment of intrathecal bolus adminis-
tration of SNP in patients with established delayed CVS.
Raabe et al. [10] studied the effect of SNP in patients with
severe, medically refractory vasospasm. They suggested
that SNP is more effective when initiated early and admin-
istered continuously.
The highly lipid-soluble calcium antagonist nimodip-
ine has been advocated in the treatment of cerebral
vasospasm because it inhibits a fundamental mechanism
involved in vasoconstriction of cerebral arteries, calcium
influx. The influx of extracellular calcium ions results
from the opening of L type calcium channels (target
of calcium antagonists) and additional channels such
as store operated-channels [43]. Lack of prevention of
CVS and systemic side effects with oral or intravenous
administration led to experiments with topical application.
Voldby et al. [26] studied the effect of intrathecal bolus
administration of calcium antagonist nimodipine after
experimental SAH in dogs. Nimodipine always relieved
spasm and often the relaxation surpassed the resting
vessel diameter, whereas in a control group the injection
of placebo did not relax the spastic arteries [26]. Goia
et al. [27] and Zabramski et al. [32] found beneficial
effect on intrathecal nimodipine as opposed to systemic
administration in reversing angiographic vasospasm in
the two-hemorrhage and multihemorrhage canine models.
Based on these promising data derived from experimental
studies on topical nimodipine, first clinical trials have
been carried out using perivascular administration of
the drug [24, 25, 28]. Despite promising results form
these trials and previous experimental studies (Table 2,
ESM) [24–29, 32], intrathecal administration of nimodip-
ine as a potential avenue in CVS prevention remained
controversial and fall into oblivion [29].
Not only the systemic side effects of current treatment
modalities but also the trend towards endovascular treat-
ment of ruptured aneurysms has influenced research into
alternatives for treating CVS after SAH [44, 45]. During
the procedure of craniotomy and aneurysm clipping the
vessels surrounding the bleeding site are accessible for top-
ical drug application or deposition of a polymer or place-
ment of a tube for repeated drug administration. Methods
which require surgical access to the region of interest are
less likely to be used in a patient treated with endovascu-
lar coiling. Other approaches are likely to generate more
interest, such as administration through lumbar puncture
and advancement of a microcatheter and microguidewire
to the ventral cisterna magna under fluoroscopic visualiza-
tion or administration via conventional external ventricular
drain.
In bleeding sites, independently of intrathecal drug ap-
plication, the ability of the drug to reach the target may be
impaired by clotting or abnormal cerebrospinal fluid cir-
culation. Thomas et al. [8, 9] argue that the drug (in their
experiment SNP) may penetrate the brain parenchyma by
way of the ventricle’s ependyma. In this hypothesis the
drug becomes independent of ventricular CSF circulation
but still does not bypass the problem of clot penetration. It
remains unclear whether a high drug concentration in close
vicinity to the clot is necessary.
In the presented model intrathecal administration is
carried out at the same location where the experimental
SAH occurred. Nearly all experiments performed are
based on this principle of drug administration at the bleed-
ing site. This selectivity is barely conceivable in a clinical
setting. Therefore the results from the current study should
be evaluated in a model in which the SAH bleeding site is
independent of the intrathecal drug administration.
The remarkable vasospasms in the control group (no
SAH/NaCl) may have occurred due to aseptic inflamma-
tory response to mechanical disruption [46]. In the begin-
ning of experimental CVS research mechanical stimula-
tion was used to induce arterial narrowing [46, 47]. Other
authors with a similar setting of continuous intracisternal
drug infusion to attenuate SAH induced CVS do not re-
port a control group of saline infusion and therefore the
possibility to compare our findings lacks [48]. However,
the results indicate that the placement of drug administra-
tion devices in the vicinity of the examined vessel could
be unfavorable. Independent location of drug administra-
tion from the bleeding site would avoid any local interac-
tion and drug penetration to the affected vessel could be
determined. Eligible would be the use of a ventriculosub-
arachnoid cannula, with the possibility of continuous drug
administration and simultaneous measurement of intracra-
nial pressure through the same cranial screw device [49].
In this set-up possible side effects of additional fluid de-
rived from drug administration can be monitored by the
ICP parameter.
The results show no statistically significant difference
between no SAH/treatment and SAH/treatment groups,
which indicates that both nimodipine and GTN are potent
in preventing delayed cerebral vasospasm associated with
either experimental SAH or pump implantation. In the
current understanding of delayed cerebral vasospasm
nimodipine and NO donor GTN are acting at the bot-
tom of the pathophysiological cascade and may prevent
vasospasm on an unspecific basis, irrespective of the
initially underlying cause (chemical stimulation by sub-
arachnoid blood or mechanical stimulation by pump im-
plantation).
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The findings of this study warrant further investigations
into the dose-dependency effects of continuous intrathecal
infusion NO donors and nimodipine in a modified rabbit
model with intraventricular drug delivery. Based on current
clinical treatment modalities after SAH, an experimental
setting with an intrathecal administration site that differs
from the bleeding site is needed to confirm these results as
a potential preventive treatment option in SAH-associated
CVS.
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